.jpg)
ATR inhibitors
WO2014140644
The CNIO has developed inhibitors of ataxia telangiectasia mutated and Rad3-related kinase (ATR). The inventors have found novel chemical entities with anti-cancer activity, and more specifically to chemical entities that inhibit ATR (Ataxia telangiectasia mutated and Rad3-related kinase). This invention also relates to pharmaceutical compositions containing, and the uses of, such chemical entities.
The present invention relates to a series of tricyclic chemical entities that are inhibitors of ATR. These chemical entities demonstrate good selectivity for ATR and are potentially useful in the treatment of cancer. The invention further relates to pharmaceutical compositions of the chemical entities, to the use of the compositions as therapeutic agents, and to methods of treatment using these compositions. In an aspect, the present invention provides chemical entities selected from compounds of formula (I).